Subject:
- Active Substance: Canagliflozin
- Name: Invokana®
- Therapeutic area: Type-2 Diabetes mellitus
- Pharmaceutical company: Janssen-Cilag GmbH
Time table:
- Publication of final assessment: 26.02.2014
Assessment information:
- Title: Canagliflozin for the treatment of type 2 diabetes mellitus
- Author/Co-Author: AAZ (Croatia), FIMEA (Finland), PRIHTA (Italy)
- Dedicated Reviewers: CAHIAQ (Spain), HAS (France), HVB (Austria), MU Sofia (Bulgaria), MoH Czech (Czech Republic)
› G-BA assessment available (D-101)